It is currently Tue Sep 02, 2014 2:55 pm

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Early development of anti-natalizumab antibodies in MS

Early development of anti-natalizumab antibodies in MS patients

Abstract

The purpose of this study is to monitor the development of anti-natalizumab antibodies to evaluate their first appearance in multiple sclerosis patients, since their presence has been associated with a reduction in the efficacy of the treatment and an increase of adverse events...... Read More - http://www.ms-uk.org/index.cfm/tysabri
Read more : Early development of anti-natalizumab antibodies in MS | Views : 706 | Replies : 1


update on Tysabri--August 2013

According to e-healthme, a reporting site which is based on reports by the FDA and self-reporting of actual patients, on May 22, 2013--
90,168 people reported to have side effects when taking Tysabri.
Among them, 665 people (0.74%) have died.
http://www.ehealthme.com/ds/tysabri/death
359 people are currently reported to have PML.
http://chefarztfrau.de/?page_id=716

But there have been more Tysabri deaths documented, linked to antibody reactions, lethal ...
Read more : update on Tysabri--August 2013 | Views : 2160 | Replies : 13


Now 359 cases of PML!

Unfortunately the Tysabri related cases of PML have jumped 12 from last month bringing the new total to 359. Don't know if there has been any additional deaths. It isn't getting any better.

http://chefarztfrau.de/?page_id=716

Harry
Read more : Now 359 cases of PML! | Views : 832 | Replies : 0


Need Name of Doctor for PML Management and Treatment ASAP

Has anyone had current or recent experience with PML?
Whom, in addition to Biogen, should be contacted for consultation for PML management and treatment?
Who are the expert doctors in this field?
My nephew is currently hospitalized and getting his second session of plasma exchange for PML treatment. He was on Tysabri for five years and was just diagnosed with PML.
Thank you.
Read more : Need Name of Doctor for PML Management and Treatment ASAP | Views : 2382 | Replies : 18


Any Tysabri users want to change my mind?

Just took my blood test to find out if I have the JC virus(hope I spelled right). If I am negative, the neurologist strongly recommends Tysabri. If I am positive, then they want to go with Avonex. Being the positive person that I am at 35, I'm thinking I am gonna be negative. So anyone out there in this MS world want to tell me their experience with Tysabri? Anything I should prepare for? I ...
Read more : Any Tysabri users want to change my mind? | Views : 2065 | Replies : 20


Natalizumab treatment reduces fatigue in multiple sclerosis

Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue.

Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue...... Read More - http://www.ms-uk.org/index.cfm/tysabri
Read more : Natalizumab treatment reduces fatigue in multiple sclerosis | Views : 974 | Replies : 1


Biogen Idec gains commercial rights of Tysabri from Elan

Biogen Idec gains commercial rights of Tysabri from Elan Corporation

Biogen Idec has completed its purchase of Elan Corporation’s interest in Tysabri (natalizumab) and has gained full strategic, commercial and decision-making rights of Tysabri. The transaction was originally announced on February 6, 2013....................Read More - http://www.ms-uk.org/index.cfm/tysabri
Read more : Biogen Idec gains commercial rights of Tysabri from Elan | Views : 782 | Replies : 1


New Tysabri And Anti-JCV Antibody Stability Data Released

New Tysabri And Anti-JCV Antibody Stability Data Released

Biogen Idec and Elan Corporation, plc announced results from several studies of Tysabri(R) (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status stability, and suggest better outcomes when progressive multifocal leukoencephalopathy (PML) is detected early. These data will be presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego.........Read ...
Read more : New Tysabri And Anti-JCV Antibody Stability Data Released | Views : 1168 | Replies : 0


Early Magnetic Resonance Detection Natalizumab-Related PML

Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis

Diagnosis of progressive multifocal leukoencephalopathy is usually based on the clinical presentation, on the demonstration of the brain lesions at the magnetic resonance imaging examination, and on the detection of the JC virus DNA in the cerebrospinal fluid with high sensitive polymerase chain reaction..... Read More - http://www.ms-uk.org/index.cfm/tysabri
Read more : Early Magnetic Resonance Detection Natalizumab-Related PML | Views : 747 | Replies : 0


Early Detection of MS Treatment Complication May Improve...

Early Detection of MS Treatment Complication May Improve Survival

The drug natalizumab is effective for treating multiple sclerosis (MS), but it increases the risk of a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy (PML). A study released today that will be presented at the American Academy of Neurology’s 65th Annual Meeting in San Diego, March 16 to 23, 2013, suggests that early detection of PML may help improve survival and disability levels. ...
Read more : Early Detection of MS Treatment Complication May Improve... | Views : 734 | Replies : 1


 

Login  •  Register


Statistics

Total posts 219670 • Total topics 22680 • Total members 14296


Contact us | Terms of Service